|1.||Garaci, Enrico: 6 articles (10/2012 - 08/2003)|
|2.||Romani, Luigina: 5 articles (04/2010 - 10/2006)|
|3.||Rasi, Guido: 5 articles (11/2007 - 08/2003)|
|4.||Bozza, Silvia: 4 articles (04/2010 - 10/2006)|
|5.||Bonifazi, Pierluigi: 4 articles (04/2010 - 10/2006)|
|6.||Bistoni, Francesco: 4 articles (11/2007 - 10/2006)|
|7.||Shen, Feng: 3 articles (01/2015 - 05/2004)|
|8.||Tuthill, Cynthia: 3 articles (01/2015 - 06/2005)|
|9.||Li, Ning: 3 articles (04/2014 - 11/2004)|
|10.||Pierimarchi, Pasquale: 3 articles (10/2012 - 08/2003)|
|1.||Chronic Hepatitis B
09/01/1999 - "Previous clinical trials have suggested that thymosin alpha1 (Talpha1), an immunomodulatory peptide, may be effective in the treatment of chronic hepatitis B (CHB). "
01/01/1999 - "Thymosin alpha1, an immunomodulatory endogenous peptide, has been shown to be effective in the treatment of chronic hepatitis B and C. "
05/01/1998 - "Thymosin alpha1 (Talpha) is an immune modifier that has been shown in a pilot study to be effective for chronic hepatitis B; this requires confirmation. "
10/01/2003 - "The efficacy of thymosin alpha 1 (Talpha1) in patients with chronic hepatitis B still requires confirmation. "
05/01/1998 - "Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial."
01/01/2015 - "Combination of thymalfasin significantly improved survival and prolonged the time to tumor recurrence in patients who received transcatheter arterial chemoembolization after tumor resection. "
08/01/2003 - "Treatment of thymosin alpha 1 increased the number of CD4 cells and improved the NK activity, and also improved the quality of life of the elderly patients with malignant tumor. "
05/01/1985 - "Thymosin alpha 1, in vitro, was associated with improvement in LMI in the cancer patients. "
01/01/1999 - "Thymosin alpha1 kinetics from this study are comparable to those previously obtained in Japanese volunteers or cancer patients, but may be influenced by the drug formulation used."
10/01/2015 - "Thymosin alpha 1 (Tα1) is commonly used for treating several diseases; however its usage has been limited because of poor penetration of the target tissue, such as tumor cells. "
01/01/2013 - "The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial."
01/01/2009 - "[Evaluation of efficacy of thymosin alpha1 in the treatment of sepsis: a systematic review]."
01/01/2013 - "In light of the crucial role of immunologic derangement in severe sepsis, thymosin alpha 1 (Tα1) is considered as a promising beneficial immunomodulatory drug. "
03/01/2009 - "CBP and thymosin alpha1 could increase cellular immunity in patients with severe sepsis, promote recovery of organ function and improve prognosis. "
03/01/2009 - "To discuss the effect of continuous blood purification (CBP), thymosin alpha1 and combined therapy on cellular immunity in patients with severe sepsis. "
08/14/2009 - "Thymosin alpha 1 (Talpha1) is a naturally occurring thymic peptide and has previously been shown to be a potential therapy for some immunodeficiencies, malignancies, and infections. "
10/01/2008 - "Thymalfasin has shown efficacy in the treatment of chronic HCV infection. "
11/01/2007 - "Thymosin alpha1 (Talpha1), a naturally occurring thymic peptide, is approved for treatment of some viral infections and as an immune adjuvant. "
09/01/2007 - "Thymosin alpha1 (Talpha1), first described and characterized by Allan Goldstein in 1972, is used worldwide for the treatment of some immunodeficiencies, malignancies, and infections. "
05/01/2002 - "SciClone developed and launched Talpha1, under the trade name Zadaxin, for the treatment of HBV and hepatitis C virus (HCV) infections. "
|5.||Chronic Hepatitis C
06/01/1996 - "A randomized, double-blind, placebo-controlled trial was performed to evaluate the efficacy and safety of thymosin alpha 1 (alpha 1) in treating chronic hepatitis C. "
06/01/1996 - "A double-blind, placebo-controlled, pilot trial of thymosin alpha 1 for the treatment of chronic hepatitis C."
04/01/2010 - "Immunological modifications during treatment with thymosin alpha1 plus antiviral therapy in chronic hepatitis C."
06/01/2007 - "Thymosin alpha 1 is a polypeptide with immunomodulatory properties that has been suggested to increase response rates in patients with chronic hepatitis C. "
11/01/2004 - "Thymosin alpha 1 (Ta-1) is a polypeptide with immunomodulatory properties that has been suggested to increase response rates in patients with chronic hepatitis C. "
|1.||Interferon-alpha (Interferon Alfa)
|3.||urinastatin (MR 20)
|5.||thymosin fraction 5
|4.||Drug Therapy (Chemotherapy)